Table of Content

1. Key Insights

2. Executive Summary of Schizophrenia

3. Schizophrenia Market Overview at a Glance
3.1. Market Share (%) Distribution of Schizophrenia in 2017
3.2. Market Share (%) Distribution of Schizophrenia in 2030

4. Disease Background and Overview: Schizophrenia
4.1. Introduction
4.2. Early warning signs and symptoms of schizophrenia
4.3. Risk factors of schizophrenia
4.4. Subtypes of schizophrenia
4.5. Mechanism of schizophrenia
4.6. Genetics of schizophrenia
4.7. Diagnosis
4.8. Differential Diagnosis

5. Case Reports
5.1. Remission of psychosis in treatment-resistant schizophrenia following bone marrow transplantation: A case report
5.2. Case on akathisia in an elderly female patient with schizophrenia upon concurrent use of risperidone and sertraline
5.3. Case Study: A young male with auditory hallucinations in paranoid schizophrenia

6. Epidemiology and Patient Population
6.1. Key Findings
6.2. KOL Views
6.3. Epidemiology Methodology
6.4. Total Prevalent Cases of Schizophrenia in the 7MM
6.5. Total Diagnosed Prevalent Cases of Schizophrenia in the 7MM

7. United States Epidemiology
7.1. Assumptions and Rationale
7.2. Prevalent Cases of schizophrenia in the United States
7.3. Diagnosed Prevalent cases of schizophrenia in the United States
7.4. Gender-specific Diagnosed Prevalent cases of schizophrenia in the United States
7.5. Age-specific Diagnosed Prevalent cases of schizophrenia in the United States
7.6. Severity-specific Diagnosed Prevalent cases of schizophrenia in the United States

8. EU5 Epidemiology
8.1. Germany Epidemiology
8.1.1. Assumptions and Rationale
8.1.2. Prevalent Cases of schizophrenia in Germany
8.1.3. Diagnosed Prevalent cases of schizophrenia in Germany
8.1.4. Gender-specific Diagnosed Prevalent cases of schizophrenia in Germany
8.1.5. Age-specific Diagnosed Prevalent cases of schizophrenia in Germany
8.1.6. Severity-specific Diagnosed Prevalent cases of schizophrenia in Germany
8.2. France Epidemiology
8.2.1. Assumptions and Rationale
8.2.2. Prevalent Cases of schizophrenia in France
8.2.3. Diagnosed Prevalent cases of schizophrenia in France
8.2.4. Gender-specific Diagnosed Prevalent cases of schizophrenia in France
8.2.5. Age-specific Diagnosed Prevalent cases of schizophrenia in France
8.2.6. Severity-specific Diagnosed Prevalent cases of schizophrenia in France
8.3. Italy Epidemiology
8.3.1. Assumptions and Rationale
8.3.2. Prevalent Cases of schizophrenia in Italy
8.3.3. Diagnosed Prevalent cases of schizophrenia in Italy
8.3.4. Gender-specific Diagnosed Prevalent cases of schizophrenia in Italy
8.3.5. Age-specific Diagnosed Prevalent cases of schizophrenia in Italy
8.3.6. Severity-specific Diagnosed Prevalent cases of schizophrenia in Italy
8.4. Spain Epidemiology
8.4.1. Assumptions and Rationale
8.4.2. Prevalent Cases of schizophrenia in Spain
8.4.3. Diagnosed Prevalent cases of schizophrenia in Spain
8.4.4. Gender-specific Diagnosed Prevalent cases of schizophrenia in Spain
8.4.5. Age-specific Diagnosed Prevalent cases of schizophrenia in Spain
8.4.6. Severity-specific Diagnosed Prevalent cases of schizophrenia in Spain
8.5. United Kingdom Epidemiology
8.5.1. Assumptions and Rationale
8.5.2. Prevalent Cases of schizophrenia in the UK
8.5.3. Diagnosed Prevalent cases of schizophrenia in the UK
8.5.4. Gender-specific Diagnosed Prevalent cases of schizophrenia in the UK
8.5.5. Age-specific Diagnosed Prevalent cases of schizophrenia in the UK
8.5.6. Severity-specific Diagnosed Prevalent cases of schizophrenia in the UK

9. Japan Epidemiology
9.1. Assumptions and Rationale
9.2. Prevalent Cases of schizophrenia in Japan
9.3. Diagnosed Prevalent cases of schizophrenia in Japan
9.4. Gender-specific Diagnosed Prevalent cases of schizophrenia in Japan
9.5. Age-specific Diagnosed Prevalent cases of schizophrenia in Japan
9.6. Severity-specific Diagnosed Prevalent cases of schizophrenia in Japan

10. Treatment
10.1. Acute-phase symptoms
10.2. Pre-treatment assessment
10.3. Medication (Antipsychotic)
10.4. Psychotherapy
10.5. Psychosocial Therapy
10.6. Electroconvulsive Therapy (ECT)
10.7. IPAP schizophrenia Algorithm
10.8. Treatment guidelines
10.8.1. The American Psychiatric Association (APA) practice guideline for the treatment of patients with schizophrenia
10.8.2. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations
10.8.3. Updated schizophrenia port treatment recommendations: psychosocial treatment recommendations

11. Unmet needs

12. Marketed Drugs
12.1. Key Cross
12.2. Rexulti (brexpiprazole/OPC-34712): Otsuka America Pharmaceutical/Lundbeck
12.2.1. Drug Description
12.2.2. Mechanism of Action
12.2.3. Regulatory Milestones
12.2.4. Clinical Development
12.2.5. Safety and Efficacy
12.2.6. Product Profile
12.3. Caplyta (lumateperone/ITI-007): Intra-Cellular Therapies
12.3.1. Drug Description
12.3.2. Mechanism of Action
12.3.3. Regulatory Milestones
12.3.4. Clinical Development
12.3.5. Safety and Efficacy
12.3.6. Product Profile
12.4. Latuda (lurasidone hydrochloride): Sunovion Pharmaceuticals/ Sumitomo Dainippon Pharma
12.4.1. Drug Description
12.4.2. Mechanism of Action
12.4.3. Regulatory Milestones
12.4.4. Clinical Development
12.4.5. Safety and Efficacy
12.4.6. Product Profile
12.5. Saphris (asenapine): Merck/AbbVie/Schering-Plough Corporation/Allergan
12.5.1. Drug Description
12.5.2. Mechanism of Action
12.5.3. Regulatory Milestones
12.5.4. Safety and Efficacy
12.5.5. Product Profile
12.6. Abilify MyCite (aripiprazole tablets with sensor): Otsuka Pharmaceutical
12.6.1. Drug Description
12.6.2. Mechanism of Action
12.6.3. Regulatory Milestones
12.6.4. Clinical Development
12.6.5. Safety and Efficacy
12.6.6. Product Profile
12.7. Invega Sustenna (paliperidone palmitate): Janssen Research & Development
12.7.1. Product Description
12.7.2. Regulatory Milestones
12.7.3. Clinical Development
12.7.4. Safety and Efficacy
12.7.5. Product Profile
12.8. Vraylar/Reagila (cariprazine): Gedeon Richter/AbbVie
12.8.1. Drug Description
12.8.2. Regulatory Milestones
12.8.3. Clinical Development
12.8.4. Safety and Efficacy
12.8.5. Product Profile
12.9. Adasuve (loxapine): Alexza Pharmaceuticals
12.9.1. Product Description
12.9.2. Regulatory Milestones
12.9.3. Clinical Development
12.9.4. Safety and Efficacy
12.9.5. Product Profile
12.10. Secuado (asenapine/HP-3070): Noven Pharmaceuticals/Hisamitsu Pharmaceutical
12.10.1. Drug Description
12.10.2. Regulatory Milestones
12.10.3. Clinical Development
12.10.4. Safety and Efficacy
12.10.5. Product Profile
12.11. Invega Trinza: Janssen Pharmaceuticals
12.11.1. Drug Description
12.11.2. Regulatory Milestones
12.11.3. Clinical Development
12.11.4. Safety and Efficacy
12.11.5. Product Profile
12.12. Aristada and Aristada Initio: Alkermes
12.12.1. Drug Description
12.12.2. Mechanism of Action
12.12.3. Regulatory Milestones
12.12.4. Clinical Development
12.12.5. Safety and Efficacy
12.12.6. Product Profile
12.13. Perseris (risperidone): Indivior
12.13.1. Drug Description
12.13.2. Mechanism of Action
12.13.3. Regulatory Milestones
12.13.4. Clinical Development
12.13.5. Safety and Efficacy
12.13.6. Product Profile
13. Emerging Drugs
13.1. Key Cross Competition
13.2. Doria (risperidone ISM): Rovi Pharmaceuticals Laboratories
13.2.1. Product Description
13.2.2. Other Developmental Activities
13.2.3. Clinical Development
13.2.4. Safety and Efficacy
13.2.5. Product Profile
13.3. Roluperidone (MIN-101): Minerva Neurosciences
13.3.1. Product Description
13.3.2. Other Developmental Activities
13.3.3. Clinical Development
13.3.4. Safety and Efficacy
13.3.5. Product Profile
13.4. SEP-363856: Sunovion/PsychoGenics
13.4.1. Product Description
13.4.2. Other Developmental Activities
13.4.3. Clinical Development
13.4.4. Safety and Efficacy
13.4.5. Product Profile
13.5. Pimavanserin: Acadia Pharmaceuticals
13.5.1. Product Description
13.5.2. Other developmental activity
13.5.3. Clinical Development
13.5.4. Safety and Efficacy
13.5.5. Product Profile
13.6. Encenicline (EVP-6124): Forum Pharmaceuticals
13.6.1. Product Description
13.6.2. Other developmental activity
13.6.3. Clinical Development
13.6.4. Safety and Efficacy
13.6.5. Product Profile
13.7. Dexmedetomidine (BXCL501): BioXcel Therapeutics
13.7.1. Product Description
13.7.2. Other Developmental Activities
13.7.3. Clinical Development
13.7.4. Safety and Efficacy
13.7.5. Product Profile
13.8. Avisetron (AVN-211): Avineuro Pharmaceuticals
13.8.1. Product Description
13.8.2. Other Developmental Activity
13.8.3. Clinical Development
13.8.4. Safety and Efficacy
13.8.5. Product Profile
13.9. ALKS 3831 (Olanzapine + Samidorphan): Alkermes
13.9.1. Product Description
13.9.2. Other Developmental Activities
13.9.3. Clinical Development
13.9.4. Safety and Efficacy
13.9.5. Product Profile
13.10. AVP-786: Avanir Pharmaceuticals/Otsuka Pharmaceutical/Concert Pharmaceuticals
13.10.1. Product Description
13.10.2. Other Developmental Activities
13.10.3. Clinical Development
13.10.4. Product Profile
13.11. Lu AF11167: H. Lundbeck A/S
13.11.1. Product Description
13.11.2. Other Developmental Activities
13.11.3. Clinical Development
13.11.4. Product Profile
13.12. GWP42003 (Cannabidiol/GWP42003-P): GW Research
13.12.1. Product Description
13.12.2. Clinical Development
13.12.3. Safety and Efficacy
13.12.4. Product Profile
13.13. BI 409306: Boehringer Ingelheim
13.13.1. Product Description
13.13.2. Other Developmental Activities
13.13.3. Clinical Development
13.13.4. Safety and Efficacy
13.13.5. Product Profile
13.14. KarXT: Karuna Pharmaceuticals
13.14.1. Product Description
13.14.2. Other developmental activity
13.14.3. Clinical Development
13.14.4. Safety and Efficacy
13.14.5. Product Profile
13.15. TAK-831: Takeda
13.15.1. Product Description
13.15.2. Other Developmental Activities
13.15.3. Clinical Development
13.15.4. Product Profile
13.16. NaBen (Sodium Benzoate): SyneuRx International
13.16.1. Product Description
13.16.2. Other Developmental Activities
13.16.3. Clinical Development
13.16.4. Product Profile
13.17. BI 425809: Boehringer Ingelheim
13.17.1. Product Description
13.17.2. Other developmental activity
13.17.3. Clinical Development
13.17.4. Safety and Efficacy
13.17.5. Product Profile
13.18. BIIB104 (AMPA): Biogen
13.18.1. Product Description
13.18.2. Other developmental activity
13.18.3. Clinical Development
13.18.4. Safety and Efficacy
13.18.5. Product Profile
13.19. RO6889450: Roche
13.19.1. Product Description
13.19.2. Clinical Development
13.19.3. Product Profile
13.20. PF-06412562: Cerevel Therapeutics/Pfizer
13.20.1. Product Description
13.20.2. Other developmental activity
13.20.3. Clinical Development
13.20.4. Safety and Efficacy
13.20.5. Product Profile
13.21. CTP-692: Concert Pharmaceuticals
13.21.1. Product Description
13.21.2. Other Developmental Activity
13.21.3. Clinical Development
13.21.4. Product Profile
13.22. Evenamide (NW-3509/NW-3509A): Newron Pharmaceuticals
13.22.1. Product Description
13.22.2. Other Developmental Activity
13.22.3. Clinical Development
13.22.4. Safety and Efficacy
13.22.5. Product Profile
13.23. Miricorilant: Corcept Therapeutics
13.23.1. Product Description
13.23.2. Clinical Development
13.23.3. Product Profile
13.24. MK-8189: Merck
13.24.1. Product Description
13.24.2. Clinical Development
13.24.3. Product Profile
13.25. CPL500036: Celon Pharma
13.25.1. Product Description
13.25.2. Other Developmental Activities
13.25.3. Clinical Development
13.25.4. Safety and Pharmacokinetics
13.25.5. Product Profile

14. Key Endpoints

15. Schizophrenia: 7MM Market Analysis
15.1. Key Findings
15.2. Market Methodology
15.3. Attribute Analysis
15.4. Market Size of Schizophrenia in the 7MM
15.5. Market Size of Schizophrenia by Therapies in the 7MM
15.5.1. Market Size of Schizophrenia by Class in the 7MM
15.5.2. Market Size of Schizophrenia by Current and Emerging Therapies in the 7MM

16. United States Market Outlook
16.1. United States Market Size
16.2. Total market size of Schizophrenia in the United States
16.3. Market Size of Schizophrenia by Therapies in the US

17. EU-5 Market Outlook
17.1. Germany Market Size
17.1.1. Total Market size of Schizophrenia in Germany
17.1.2. Market Size of Schizophrenia by Therapies in Germany
17.2. France Market Size
17.2.1. Total Market size of Schizophrenia in France
17.2.2. Market Size of Schizophrenia by Therapies in France
17.3. Italy Market Size
17.3.1. Total Market size of Schizophrenia in Italy
17.3.2. Market Size of Schizophrenia by Therapies in Italy
17.4. Spain Market Size
17.4.1. Total Market size of Schizophrenia in Spain
17.4.2. Market Size of Schizophrenia by Therapies in Spain
17.5. United Kingdom Market Size
17.5.1. Total Market size of Schizophrenia in the United Kingdom
17.5.2. Market Size of Schizophrenia by Therapies in the UK

18. Japan Market Outlook
18.1. Japan Market Size
18.1.1. Total Market size of Schizophrenia in Japan
18.1.2. Market Size of Schizophrenia by Therapies in Japan

19. Key Market Forecast Assumptions

20. Market Drivers
21. Market Barriers
22. SWOT Analysis
23. Reimbursement and Market Access
24. Appendix
24.1. Bibliography
24.2. Report Methodology
25. DelveInsight Capabilities
26. Disclaimer
27. About DelveInsight



List of Figures


Figure 1 Overview of Schizophrenia
Figure 2 Interaction of genetic and environmental risk factors in the developmental pathology of schizophrenia
Figure 3 Neuron–glia interactions in the cerebral cortex?key neural substrates for the pathology of schizophrenia
Figure 4 Schematic representation of drug actions that normalize aberrant glutamate neurotransmission in the prefrontal cortex of schizophrenics
Figure 5 A representative molecular pathway for schizophrenia?fine-tuning of the glutamate synapse
Figure 6 KOL Views
Figure 7 KOL Views
Figure 8 Total Prevalent Cases of Schizophrenia in the 7MM (2017–2030)
Figure 9 Total Diagnosed Prevalent Cases of Schizophrenia in the 7MM (2017–2030)
Figure 10 Prevalent cases of schizophrenia in the United States (2017–2030)
Figure 11 Diagnosed Prevalent cases of schizophrenia in the United States (2017–2030)
Figure 12 Gender-specific Diagnosed Prevalent cases of schizophrenia in the United States (2017–2030)
Figure 13 Age-specific Diagnosed Prevalent cases of schizophrenia in the United States (2017–2030)
Figure 14 Severity-specific Diagnosed Prevalent cases of schizophrenia in the United States (2017–2030)
Figure 15 Prevalent cases of schizophrenia in Germany (2017–2030)
Figure 16 Diagnosed Prevalent cases of schizophrenia in Germany (2017–2030)
Figure 17 Gender-specific Diagnosed Prevalent cases of schizophrenia in Germany (2017–2030)
Figure 18 Age-specific Diagnosed Prevalent cases of schizophrenia in Germany (2017–2030)
Figure 19 Severity-specific Diagnosed Prevalent cases of schizophrenia in Germany (2017–2030)
Figure 20 Prevalent cases of schizophrenia in France (2017–2030)
Figure 21 Diagnosed Prevalent cases of schizophrenia in France (2017–2030)
Figure 22 Gender-specific Diagnosed Prevalent cases of schizophrenia in France (2017–2030)
Figure 23 Age-specific Diagnosed Prevalent cases of schizophrenia in Germany (2017–2030)
Figure 24 Severity-specific Diagnosed Prevalent cases of schizophrenia in France (2017–2030)
Figure 25 Prevalent cases of schizophrenia in Italy (2017–2030)
Figure 26 Diagnosed Prevalent cases of schizophrenia in Italy (2017–2030)
Figure 27 Gender-specific Diagnosed Prevalent cases of schizophrenia in Italy (2017–2030)
Figure 28 Age-specific Diagnosed Prevalent cases of schizophrenia in Germany (2017–2030)
Figure 29 Severity-specific Diagnosed Prevalent cases of schizophrenia in Italy (2017–2030)
Figure 30 Prevalent cases of schizophrenia in Spain (2017–2030)
Figure 31 Diagnosed Prevalent cases of schizophrenia in Spain (2017–2030)
Figure 32 Gender-specific Diagnosed Prevalent cases of schizophrenia in Spain (2017–2030)
Figure 33 Age-specific Diagnosed Prevalent cases of schizophrenia in Spain (2017–2030)
Figure 34 Severity-specific Diagnosed Prevalent cases of schizophrenia in Spain (2017–2030)
Figure 35 Prevalent cases of schizophrenia in the UK (2017–2030)
Figure 36 Diagnosed Prevalent cases of schizophrenia in the UK (2017–2030)
Figure 37 Gender-specific Diagnosed Prevalent cases of schizophrenia in the UK (2017–2030)
Figure 38 Age-specific Diagnosed Prevalent cases of schizophrenia in the UK (2017–2030)
Figure 39 Severity-specific Diagnosed Prevalent cases of schizophrenia in the UK (2017–2030)
Figure 40 Prevalent cases of schizophrenia in Japan (2017–2030)
Figure 41 Diagnosed Prevalent cases of schizophrenia in Japan (2017–2030)
Figure 42 Gender-specific Diagnosed Prevalent cases of schizophrenia in Japan(2017–2030)
Figure 43 Age-specific Diagnosed Prevalent cases of schizophrenia in Japan (2017–2030)
Figure 44 Severity-specific Diagnosed Prevalent cases of schizophrenia in Japan (2017–2030)
Figure 45 Treatment approaches of schizophrenia
Figure 46 Types of medications to treat schizophrenia
Figure 47 Types of Psychotherapy to treat schizophrenia
Figure 48 Schizophrenia Algorithm
Figure 49 Unmet Needs of Schizophrenia
Figure 50 Atypical antipsychotics, or second-generation antipsychotic drugs
Figure 51 Market Size of Schizophrenia in the 7MM in USD Million (2017–2030)
Figure 52 Market Size of Schizophrenia by Class in the 7MM, in USD Million (2017–2030)
Figure 53 Market Size of Schizophrenia by Current and Emerging Therapies in the 7MM, in USD Million (2017–2030)
Figure 54 Market Size of Schizophrenia in the US, USD Millions (2017–2030)
Figure 55 Market Size of Schizophrenia by Class in the US, in USD Million (2017–2030)
Figure 56 Market Size of Schizophrenia by Current and Emerging Therapies in the US, in USD Million (2017–2030)
Figure 57 Market Size of Schizophrenia in Germany, USD Millions (2017–2030)
Figure 58 Market Size of Schizophrenia by Class in Germany, in USD Million (2017–2030)
Figure 59 Market Size of Schizophrenia by Current and Emerging Therapies in Germany, in USD Million (2017–2030)
Figure 60 Market Size of Schizophrenia in France, USD Millions (2017–2030)
Figure 61 Market Size of Schizophrenia by Class in France, in USD Million (2017–2030)
Figure 62 Market Size of Schizophrenia by Current and Emerging Therapies in France, in USD Million (2017–2030)
Figure 63 Market Size of Schizophrenia in Italy, USD Millions (2017–2030)
Figure 64 Market Size of Schizophrenia by Class in Italy, in USD Million (2017–2030)
Figure 65 Market Size of Schizophrenia by Current and Emerging Therapies in Italy in USD Million (2017–2030)
Figure 66 Market Size of Schizophrenia in Spain, USD Millions (2017–2030)
Figure 67 Market Size of Schizophrenia by Class in Spain in USD Million (2017–2030)
Figure 68 Market Size of Schizophrenia by Current and Emerging Therapies in Spain in USD Million (2017–2030)
Figure 69 Market Size of Schizophrenia in the UK, USD Millions (2017–2030)
Figure 70 Market Size of Schizophrenia by Class in the UK in USD Million (2017–2030)
Figure 71 Market Size of Schizophrenia by Current and Emerging Therapies in the UK in USD Million (2017–2030)
Figure 72 Market Size of Schizophrenia in Japan, USD Millions (2017–2030)
Figure 73 Market Size of Schizophrenia by Class in Japan, in USD Million (2017–2030)
Figure 74 Market Size of Schizophrenia by Molecules of Different Class in Japan in USD Million (2017–2030)
Figure 75 Market Drivers
Figure 76 Market Barriers
Figure 77 SWOT Analysis of Schizophrenia

 

List of Tables


Table 1 Summary of Schizophrenia, Market, Epidemiology and Key Events (2017–2030)
Table 2 Early symptoms of schizophrenia
Table 3 Symptoms of Schizophrenia
Table 4 Clinical features of schizophrenia, bipolar disorder, schizoaffective disorder, autism, and ADHD
Table 5 Total Prevalent Cases of Schizophrenia in the 7MM (2017–2030)
Table 6 Total Diagnosed Prevalent Cases of Schizophrenia in the 7MM (2017–2030)
Table 7 Prevalent cases of schizophrenia in the United States (2017–2030)
Table 8 Diagnosed Prevalent cases of schizophrenia in the United States (2017–2030)
Table 9 Gender-specific Diagnosed Prevalent cases of schizophrenia in the United States (2017–2030)
Table 10 Age-specific Diagnosed Prevalent cases of schizophrenia in the United States (2017–2030)
Table 11 Severity-specific Diagnosed Prevalent cases of schizophrenia in the United States (2017–2030)
Table 12 Prevalent cases of schizophrenia in Germany (2017–2030)
Table 13 Diagnosed Prevalent cases of schizophrenia in Germany (2017–2030)
Table 14 Gender-specific Diagnosed Prevalent cases of schizophrenia in Germany (2017–2030)
Table 15 Age-specific Diagnosed Prevalent cases of schizophrenia in Germany (2017–2030)
Table 16 Severity-specific Diagnosed Prevalent cases of schizophrenia in Germany (2017–2030)
Table 17 Prevalent cases of schizophrenia in France (2017–2030)
Table 18 Diagnosed Prevalent cases of schizophrenia in France (2017–2030)
Table 19 Gender-specific Diagnosed Prevalent cases of schizophrenia in France (2017–2030)
Table 20 Age-specific Diagnosed Prevalent cases of schizophrenia in Germany (2017–2030)
Table 21 Severity-specific Diagnosed Prevalent cases of schizophrenia in France (2017–2030)
Table 22 Prevalent cases of schizophrenia in Italy (2017–2030)
Table 23 Diagnosed Prevalent cases of schizophrenia in Italy (2017–2030)
Table 24 Gender-specific Diagnosed Prevalent cases of schizophrenia in Italy (2017–2030)
Table 25 Age-specific Diagnosed Prevalent cases of schizophrenia in Germany (2017–2030)
Table 26 Severity-specific Diagnosed Prevalent cases of schizophrenia in Italy (2017–2030)
Table 27 Prevalent cases of schizophrenia in Spain (2017–2030)
Table 28 Diagnosed Prevalent cases of schizophrenia in Spain (2017–2030)
Table 29 Gender-specific Diagnosed Prevalent cases of schizophrenia in Spain (2017–2030)
Table 30 Age-specific Diagnosed Prevalent cases of schizophrenia in Spain (2017–2030)
Table 31 Severity-specific Diagnosed Prevalent cases of schizophrenia in Spain (2017–2030)
Table 32 Prevalent cases of schizophrenia in the UK (2017–2030)
Table 33 Diagnosed Prevalent cases of schizophrenia in the UK (2017–2030)
Table 34 Gender-specific Diagnosed Prevalent cases of schizophrenia in the UK (2017–2030)
Table 35 Age-specific Diagnosed Prevalent cases of schizophrenia in the UK (2017–2030)
Table 36 Severity-specific Diagnosed Prevalent cases of schizophrenia in the UK (2017–2030)
Table 37 Prevalent cases of schizophrenia in Japan (2017–2030)
Table 38 Diagnosed Prevalent cases of schizophrenia in Japan (2017–2030)
Table 39 Gender-specific Diagnosed Prevalent cases of schizophrenia in Japan (2017–2030)
Table 40 Age-specific Diagnosed Prevalent cases of schizophrenia in Japan (2017–2030)
Table 41 Severity-specific Diagnosed Prevalent cases of schizophrenia in Japan (2017–2030)
Table 42 Antipsychotic medications: available oral and short-acting intramuscular formulations and dosing considerations
Table 43 Long-acting injectable antipsychotic medications: dosing
Table 44 Key Cross of Marketed Drugs
Table 45 Rexulti (brexpiprazole), Clinical Trial Description, 2020
Table 46 Caplyta (lumateperone/ ITI-007), Clinical Trial Description, 2020
Table 47 Latuda, Clinical Trial Description, 2020
Table 48 Abilify MyCite, Clinical Trial Description, 2020
Table 49 Invega Sustenna (paliperidone palmitate), Clinical Trial Description, 2020
Table 50 Vraylar, Clinical Trial Description, 2020
Table 51 Adasuve, Clinical Trial Description, 2020
Table 52 Secuado, Clinical Trial Description, 2020
Table 53 Invega Trinza, Clinical Trial Description, 2020
Table 54 Somatuline Depot (lanreotide acetate), Clinical Trial Description, 2020
Table 55 Perseris, Clinical Trial Description, 2020
Table 56 Key Cross of Emerging Drug
Table 57 Doria (risperidone ISM), Clinical Trial Description, 2020
Table 58 Roluperidone, Clinical Trial Description, 2020
Table 59 SEP-363856, Clinical Trial Description, 2020
Table 60 Pimavanserin, Clinical Trial Description 2020
Table 61 EVP-6124, Clinical Trial Description
Table 62 BXCL501, Clinical Trial Description, 2020
Table 63 ALKS 3831, Clinical Trial Description, 2020
Table 64 AVP-786, Clinical Trial Description, 2020
Table 65 Lu AF11167, Clinical Trial Description, 2020
Table 66 GWP42003 (Cannabidiol/GWP42003-P), Clinical Trial Description, 2020
Table 67 BI 409306, Clinical Trial Description, 2020
Table 68 KarXT, Clinical Trial Description
Table 69 TAK-831, Clinical Trial Description, 2020
Table 70 NaBen (Sodium Benzoate), Clinical Trial Description, 2020
Table 71 BI 425809, Clinical Trial Description 2020
Table 72 BIIB104, Clinical Trial Description 2020
Table 73 RO6889450, Clinical Trial Description
Table 74 PF 06412562, Clinical Trial Description
Table 75 CTP-692; Clinical Trial Description,2020
Table 76 Evenamide, Clinical Trial Description,2020
Table 77 Miricorilant (CORT118335), Clinical Trial Description, 2020
Table 78 MK-8189, Clinical Trial Description, 2020
Table 79 MK-8189, Clinical Trial Description, 2020
Table 80 Market Size of Schizophrenia in the 7MM in USD Million (2017–2030)
Table 81 Market Size of Schizophrenia by Class in the 7MM, in USD Million (2017–2030)
Table 82 Market Size of Schizophrenia by Current and Emerging Therapies in the 7MM, in USD Million (2017–2030)
Table 83 The US Market Size of Schizophrenia in USD Million (2017–2030)
Table 84 Market Size of Schizophrenia by Therapies in the US, in USD Million (2017–2030)
Table 85 Market Size of Schizophrenia by Current and Emerging Therapies in the US, in USD Million (2017–2030)
Table 86 Germany Market Size of Schizophrenia in USD Million (2017–2030)
Table 87 Market Size of Schizophrenia by Therapies in Germany, in USD Million (2017–2030)
Table 88 Market Size of Schizophrenia by Current and Emerging Therapies in Germany, in USD Million (2017–2030)
Table 89 France Market Size of Schizophrenia in USD Million (2017–2030)
Table 90 Market Size of Schizophrenia by Class in France, in USD Million (2017–2030)
Table 91 Market Size of Schizophrenia by Current and Emerging Therapies in France, in USD Million (2017–2030)
Table 92 Italy Market Size of Schizophrenia in USD Million (2017–2030)
Table 93 Market Size of Schizophrenia by Class in Italy, in USD Million (2017–2030)
Table 94 Market Size of Schizophrenia by Current and Emerging Therapies in Italy, in USD Million (2017–2030)
Table 95 Spain Market Size of Schizophrenia in USD Million (2017–2030)
Table 96 Market Size of Schizophrenia by Therapies in Spain, in USD Million (2017–2030)
Table 97 Market Size of Schizophrenia by Current and Emerging Therapies in Spain, in USD Million (2017–2030)
Table 98 The UK Market Size of Schizophrenia in USD Million (2017–2030)
Table 99 Market Size of Schizophrenia by Class in the UK, in USD Million (2017–2030)
Table 100 Market Size of Schizophrenia by Current and Emerging Therapies in the UK, in USD Million (2017–2030)
Table 101 Japan Market Size of Schizophrenia in USD Million (2017–2030)
Table 102 Market Size of Schizophrenia by Class in Japan, in USD Million (2017–2030)
Table 103 Market Size of Schizophrenia by Current and Emerging Therapies in Japan, in USD Million (2017–2030)
Table 104 Key Market Forecast Assumptions for Roluperidone (MIN-101)
Table 105 Key Market Forecast Assumptions for Dexmedetomidine (BXCL501)
Table 106 Key Market Forecast Assumptions for SEP363856
Table 107 Key Market Forecast Assumptions for Pimavanserin
Table 108 Key Market Forecast Assumptions for Risperidone ISM (DORIA)
Table 109 Key Market Forecast Assumptions for ALKS 3831
Table 110 Key Market Forecast Assumptions for Evenamide
Table 111 Key Market Forecast Assumptions for BI 409306
Table 112 Key Market Forecast Assumptions for GWP42003-P
Table 113 Key Market Forecast Assumptions for KarXT